Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Wrishko, Rebecca E; McCrea, Jacqueline B; Yee, Ka Lai; Liu, Wen; Panebianco, Deborah; Mangin, Eric; Chakravarthy, Manu; Martinez-Cantarin, Maria P; Kraft, Walter K

Wrishko, Rebecca E; McCrea, Jacqueline B; Yee, Ka Lai; Liu, Wen; Panebianco, Deborah; Mangin, Eric; Chakravarthy, Manu; Martinez-Cantarin, Maria P; Kraft, Walter K.

Afiliação

Wrishko RE; Merck & Co., Inc., Kenilworth, NJ, USA.
McCrea JB; Merck & Co., Inc., Kenilworth, NJ, USA. jackie_mccrea@merck.com.
Yee KL; Merck & Co., Inc., Kenilworth, NJ, USA.
Liu W; Merck & Co., Inc., Kenilworth, NJ, USA.
Panebianco D; Merck & Co., Inc., Kenilworth, NJ, USA.
Mangin E; Merck & Co., Inc., Kenilworth, NJ, USA.
Chakravarthy M; Merck & Co., Inc., Kenilworth, NJ, USA.
Martinez-Cantarin MP; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Kraft WK; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.

Clin Drug Investig ; 39(5): 453-454, 2019 May.

Article em En | MEDLINE | ID: mdl-30895461

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Clin Drug Investig Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google